Evidence map›Paper›PMID 40400394›Full record

ArticleJournal of medical virology2025

Clinical and Epidemiological Insights into a Parainfluenza Virus Type 3 Outbreak in Multiple Myeloma Patients.

Sarah Timsit, Guillaume Mellon, Nathalie Forgeard, Séverine Mercier-Delarue, Nadia Mahjoub, Victor Euzen, Stéphanie Harel, Dikelele Elessa, Nathalie Osinski, Elise Diaz and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sarah TimsitVirology Department, AP-HP, Hôpital Saint Louis, Paris, France.ORCID 0009-0003-3508-4558
Guillaume MellonInfection Prevention and Control Unit, AP-HP, Hôpital Saint-Louis, Paris, France.
Nathalie ForgeardImmuno-Hematology Department, AP-HP, Hôpital Saint-Louis, Paris, France.
Séverine Mercier-DelarueVirology Department, AP-HP, Hôpital Saint Louis, Paris, France.
Nadia MahjoubVirology Department, AP-HP, Hôpital Saint Louis, Paris, France.
Victor EuzenVirology Department, AP-HP, Hôpital Saint Louis, Paris, France.
Stéphanie HarelImmuno-Hematology Department, AP-HP, Hôpital Saint-Louis, Paris, France.
Dikelele ElessaImmuno-Hematology Department, AP-HP, Hôpital Saint-Louis, Paris, France.
Nathalie OsinskiInfection Prevention and Control Unit, AP-HP, Hôpital Saint-Louis, Paris, France.
Elise DiazUniversité Paris Cité, Inserm U976, Insight Team, Paris, France.
Bruno RoyerImmuno-Hematology Department, AP-HP, Hôpital Saint-Louis, Paris, France.
Bertrand ArnulfImmuno-Hematology Department, AP-HP, Hôpital Saint-Louis, Paris, France.
Maud SalmonaVirology Department, AP-HP, Hôpital Saint Louis, Paris, France.ORCID 0000-0001-7985-6132
Jérôme LegoffVirology Department, AP-HP, Hôpital Saint Louis, Paris, France.ORCID 0000-0001-7111-1865

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human parainfluenza virus type 3 (HPIV-3) can be responsible for mild to severe respiratory infections and hospital epidemics. We investigated an outbreak in a hematology unit. Respiratory viruses were screened using multiplex PCR. HPIV-3 quantification and whole-genome sequencing were performed on HPIV-3 positive respiratory samples. Clinical characteristics, infection progression, incidence rates of respiratory viruses within the hospital and detection of respiratory viruses were documented, along with the reinforcement of infection prevention and control (IPC) measures implemented. Between November 2022, and January 2023, HPIV-3 was identified in 20 of 113 hematology patients (17.7%), of whom 80% had multiple myeloma. A majority of HPIV-3-positive patients developed pneumonia (60%), and mortality was notably higher (35%) compared to patients who were negative (3%, p < 0.0001). Respiratory HPIV-3 viral loads were similar between patients with and without pneumonia. In parallel, HPIV-3 incidence in the hospital overall was lower than in the hematology unit (p < 0.0001). Air virus screening showed the detection of HPIV-3 in the air in different areas, and whole-genome sequencing confirmed the circulation of a single HPIV-3 strain. Strengthened IPC measures were associated with the containment of the outbreak. HPIV-3 has high epidemic potential in patients with multiple myeloma and causes severe infections. Our findings highlight the need for routine HPIV-3 testing in hematology units.

Indexed as

Disease OutbreaksMultiple MyelomaParainfluenza Virus 3, HumanRespiratory Tract InfectionsRespirovirus InfectionsAdultAgedAged, 80 and overFemaleHumansIncidenceMaleMiddle AgedViral LoadWhole Genome Sequencingair detectionhematologyHPIV‐3infection and prevention controloutbreakpneumoniaviral loadwhole genome sequencing

Identifiers

PMID40400394
PMCPMC12096141

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.